RIGL
Rigel Pharmaceuticals, Inc.
RIGL
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth f
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript